| AgaPharm is a private biotechnology company developing a breakthrough
drug that prevents or slows down the onset of blindness in diabetics,
and the formation of diabetic cataracts.
It is a prescription eye drop that patients will use daily
for the rest of their lives. The drug will provide a safe and
cost-effective prevention and treatment option that addresses
significant unmet medical needs for millions of people.
The active ingredient in our drug has already been tested
in humans with few side effects. As a result, AgaPharm provides
VCs seeking near-term, high-value exits the opportunity to
quickly create value using a proven drug development method
to shorten development times, lower costs and reduce risks.
Studies completed to date by our research partner, Canada's
National Research Council, suggest the drug has considerable
promise. When successful in clinical trials, it may replace
surgery as the treatment of choice for combating blindness
caused by diabetes.
| 
